ArticleBMC immunology2025
Analysis of the clinical characteristics of poor immunological reconstitution in AIDS patients after long-term antiviral therapy in Xinjiang, China.
Article in BMC immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the clinical characteristics of poor immunological reconstitution in AIDS patients after long-term antiviral therapy in the Xinjiang region and to analyze the possible factors leading to poor immunological reconstitution.
methodsWe enrolled 735 AIDS patients who received HAART and followed up for at least 96 weeks at the Infection and Liver Disease Center of the First Affiliated Hospital of Xinjiang Medical University from March 2004 to February 2021. The clinical characteristics of all patients were summarized, and univariate and multivariate statistical analyses were performed on general conditions, clinical data, laboratory tests, and other factors.
resultsAmong the 735 patients, 506 were male (68.8%) and 229 were female (31.2%). The average age was 40.11 ± 11.88 years. The incidence rate of poor immunological reconstitution was 12.7% (94 patients). Univariate analysis showed that age at the start of antiviral therapy (P < 0.05), presence of opportunistic infections in the last three months (P < 0.05), herpes zoster symptoms before treatment (P < 0.05), WHO clinical staging (P < 0.05), and lower levels of CD4 + T lymphocyte count, CD4/CD8 ratio, lymphocyte count, hemoglobin, and albumin were significant factors. Multivariate logistic regression identified presence of herpes zoster (OR = 5.668, 95% CI: 2.312–12.769, P < 0.01), lower CD4 + T lymphocyte count (OR = 0.008, 95% CI: 0.002–0.027, P < 0.01), and reduced albumin levels (OR = 3.428, 95% CI: 1.487–7.896, P < 0.01) as independent risk factors.
conclusionEarly intervention and comprehensive assessment are essential to reduce the incidence of poor immunological reconstitution, providing insights for clinical practice and public health strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.